Filing Flows › Kymera Therapeutics (KYMR) › Stock forecast & fair value
Kymera Therapeutics (KYMR) stock forecast and price target
Kymera Therapeutics (KYMR) trades at $131.73. 23 analysts' median price target is $144.00 (+9%), from $116.00 to $180.00.
Kymera Therapeutics' latest quarter
Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for KYMR stock?
The median of 23 analysts' 12-month targets is $144.00, +9% from $131.73; the range is $116.00 to $180.00. The average rating is strong buy.
Does Kymera Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is KYMR stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.